Evaluation & Reporting of Data: How to provide a (robust) study summary

Similar documents
How to bring your registration dossier in compliance with REACH Tips and Hints Part 2

Dossier Quality Assistant

Webinar: use of alternative methods to animal testing in your REACH registration

RISK MANAGEMENT OPTION ANALYSIS CONCLUSION DOCUMENT

ANNEX IX STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 100 TONNES OR MORE ( 1 )

Survey results - Analysis of higher tier studies submitted without testing proposals

Justification for the selection of a substance for CoRAP inclusion

Annex II - List of enforceable provisions of REACH and CLP

Guidance on information requirements and Chemical Safety Assessment. Chapter R.7a: Endpoint specific guidance

Read-across illustrative example

Official Journal of the European Union

H4R Consortium - Substance Identification. Monday 27 th April 2015

Justification for the selection of a candidate CoRAP substance

How to bring your registration dossier in compliance with REACH Tips and Hints - Part 5

Stakeholders consultations on Info Cards and Brief Profiles

APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELs FOR 1-BROMOPROPANE (1-BP)

Committee for Risk Assessment RAC. Opinion proposing harmonised classification and labelling at EU level of potassium sorbate

STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH AN ACUTE REFERENCE DOSE

ECHA Committee for Risk Assessment: Evaluation of the Classification and Labelling of Glyphosate

Risk Management Option Analysis Conclusion Document

ANNEX XV REPORT AN ASSESSMENT OF WHETHER THE USE OF MUSK XYLENE IN ARTICLES SHOULD BE RESTRICTED IN ACCORDANCE WITH ARTICLE 69(2) OF REACH

Developmental neurotoxicity & REACH

EC Number: CAS Number: SUPPORT DOCUMENT FOR IDENTIFICATION OF AS A SUBSTANCE OF VERY HIGH CONCERN BECAUSE OF ITS CMR 1 PROPERTIES

Justification for the selection of a candidate CoRAP substance UPDATE

Room: 0D Centre Albert Borschette Rue Froissart Brussels, Belgium

The effect of REACH implementation on genotoxicity and carcinogenicity testing Jan van Benthem

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

Introduction to principles of toxicology and risk assessment

How to use new or revised in vitro test methods to address skin sensitisation

Substance Evaluation Conclusion Document EC No SUBSTANCE EVALUATION CONCLUSION. as required by REACH Article 48 and EVALUATION REPORT.

Substance Evaluation Conclusion document EC No SUBSTANCE EVALUATION CONCLUSION DOCUMENT. as required by REACH Article 48.

CATEGORY 4 - Rosin adduct esters UVCB CATEGORY JUSTIFICATION DOCUMENT

COMMENTS AND RESPONSE TO COMMENTS ON CLH: PROPOSAL AND JUSTIFICATION. Last data extracted on 10/12/2012

Substance Evaluation Conclusion document EC No SUBSTANCE EVALUATION CONCLUSION DOCUMENT. as required by REACH Article 48.

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use

CONTACT DETAILS: EUROPEAN CHEMICALS AGENCY. Annankatu 18, P.O. Box 400, Helsinki, Finland. tel: ,

Substance Name: Silicic acid, lead salt. EC Number: CAS Number: MEMBER STATE COMMITTEE SUPPORT DOCUMENT FOR IDENTIFICATION OF

OECD QSAR Toolbox v.4.2. An example illustrating RAAF scenario 6 and related assessment elements

FÜR RISIKOBEWERTUNG BUNDESINSTITUT

Substance Name: Sulfurous acid, lead salt, dibasic. EC Number: CAS Number: SUPPORT DOCUMENT FOR IDENTIFICATION OF

1,1 - iminodipropan-2-ol

OpenFoodTox and Other Open Source In silico EFSA. Jean Lou Dorne Senior Scientific Officer Scientific Committee and Emerging Risks Unit EFSA

Reproductive toxicity classification under CLP (Regulation (EC) no 1272/2008 on Classification, Labelling and Packaging of chemicals)

Risk Management Option Analysis Conclusion Document

We are concerned that the focus of the document is on the estrogen, androgen, thyroid, and

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

PHENOXY HERBICIDES CASE STUDY CONSIDERED IN CONTEXT OF ECHA RAAF

ANNEX 4 TO FINAL REPORT

Justification Document for the Selection of a CoRAP Substance

The proposed classification is Skin Sens. 1B H317 and the current classification is Skin Sens. 1 H317.

Public Assessment Report Scientific discussion. Trelema (lacosamide) SE/H/1648/01-07/DC

COMMISSION REGULATION (EU)

Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology

Ian Indans Regulatory scientist Chemicals Regulation Directorate (CRD)

What is an Infocard? July 2018

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

Explanatory note. On an opinion proposing harmonised classification and labelling at EU level of. glyphosate (ISO); N-(phosphonomethyl)glycine

CHEMICAL SAFETY REPORT EXECUTIVE SUMMARY

European Food Safety Authority (EFSA)

Public Assessment Report Scientific discussion. Heracillin, 1 g, film-coated tablet (flucloxacillin) Asp no:

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Guidance on information requirements and Chemical Safety Assessment. Chapter R.7a: Endpoint specific guidance

Test guidelines and guidance documents in the field of plant protection products

Justification Document for the Selection of a CoRAP Substance

Comments CLH proposal Cadmium hydroxide

Substance identity - screening of the registration dossiers

Nickel : one of the strongest documented metal

Official Journal of the European Union L 109/11

Public Assessment Report Scientific discussion. Pramipexole Orion (pramipexole) SE/H/1672/01-07/DC

Substance Evaluation Conclusion document EC No SUBSTANCE EVALUATION CONCLUSION DOCUMENT. as required by REACH Article 48.

benzhydrylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammonium chloride (C.I. Basic Violet 3) 1

Overview Internal review

RCS Overview for Iron Pellets

APPLICATION FOR AUTHORISATION: ESTABLISHING A REFERENCE DOSE RESPONSE RELATIONSHIP FOR CARCINOGENICITY OF INORGANIC ARSENIC COMPOUNDS

Substance Name: imidazolidine-2-thione (2-imidazoline-2-thiol) EC Number: CAS Number: SUPPORT DOCUMENT FOR IDENTIFICATION OF

Ecopa REACH Animal Use Calculator

KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE

Biocidal Products Committee (BPC)

Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013

Committee for Risk Assessment RAC

Public Assessment Report Scientific discussion SE/H/1689/01/DC

Benzothiazole-2-thiol (2-MBT)

Statistical analysis of comparative data on composition and agronomic characteristics: new software tool and recurring issues identified

APPLICATION OF ALTERNATIVE METHODS IN THE REGULATORY ASSESSMENT OF CHEMICAL SAFETY RELATED TO HUMAN SKIN CORROSION & IRRITATION

Committee for Risk Assessment RAC

Justification for the selection of a candidate CoRAP substance

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A

Substance Name: Fatty acids, C16-18, lead salts. EC Number: CAS Number: SUPPORT DOCUMENT FOR IDENTIFICATION OF

Public Assessment Report Scientific discussion. Flucloxacillin Orion (flucloxacillin sodium) SE/H/981/03/DC

Establishing the Relevance of Health Hazard Data for GHS Classification: Adverse vs. Non-Adverse

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)

Public Assessment Report Scientific discussion. Vixantus (tadalafil) SE/H/1532/01-04/DC

Annex XV dossier. PROPOSAL FOR IDENTIFICATION OF A SUBSTANCE AS A CMR CAT 1A OR 1B, PBT, vpvb OR A SUBSTANCE OF AN EQUIVALENT LEVEL OF CONCERN

E7 Studies in Support of Special Populations: Geriatrics. Questions & Answers. Current version. dated July 6, 2010

Guideline on influenza vaccines submission and procedural requirements

Justification for the selection of a candidate CoRAP substance

Transcription:

Evaluation & Reporting of Data: How to provide a (robust) study summary Webinar on Information requirements 30 November 2009

Evaluation of all available information Step 1: Evaluation of the data quality Relevance Adequacy Reliability Step 2: Selection of key study(ies) for each endpoint Step 3: Drafting (robust) study summaries

Evaluate the data 1.1 Relevance 1.2 Adequacy 1.3 Reliability Step 1: Evaluate Klimisch scoring 2. Adequate studies available? NO YES One adequate study YES More than one adequate study Less reliable studies Step 2: Select One key study One clear key study and supporting study(ies) Different/ conflicting adequate information 3. RSS 3. RSS for key study 3. SS for supporting study(ies) WoE 3. RSS for all studies used as part of the Weight of Evidence (WoE) WoE Step 3: Draft

Step 1: Evaluation of data quality

Step 1: Evaluation of data quality a. Relevance Data and tests are appropriate for a particular hazard identification or risk characterisation Especially following questions should be considered: Has the right/appropriate/suitable test been selected? Is the test substance the same as the registered substance? Has an appropriate organism/species been tested? Is the route of exposure relevant? Has an appropriate doses/concentrations been tested? Were the critical test parameters influencing the endpoint considered adequately?

Step 1: Evaluation of data quality b. Adequacy Information is sufficient for the purpose of C&L and/or risk assessment Data should allow clear decision-making: the substance meets the criteria for classification and labelling the substance is a potential PBT/vPvB appropriate DNEL/PNEC values can be derived for risk assessment purposes data is sufficient for specific requirements

Step 1: Evaluation of data quality c. Reliability Quality of the study, method, reporting of results and conclusions Reliability can be assessed using Klimisch scoring system 1 = reliable without restrictions 2 = reliable with restriction 3 = not reliable 4 = not assignable For reliability assessment see Guidance R.4.2.

Step 1: Evaluation of data quality c. Reliability Klimisch et al. 1997 1 = reliable without restrictions: studies or data [...] generated according to generally valid and/or internationally accepted testing guidelines (preferably performed according to GLP) or in which the test parameters documented are based on a specific (national) testing guideline [...] or in which all parameters described are closely related/comparable to a guideline method. For reliability assessment see Guidance R.4.2.

Step 1: Evaluation of data quality c. Reliability Klimisch et al. 1997 4 = not assignable: studies or data [...] which do not give sufficient experimental details and which are only listed in short abstracts or secondary literature (books, reviews, etc.). For reliability assessment see Guidance R.4.2.

Evaluate the data 1.1 Relevance 1.2 Adequacy 1.3 Reliability Step 1: Evaluate Klimisch scoring 2. Adequate studies available? NO YES One adequate study YES More than one adequate study Less reliable studies Step 2: Select One key study One clear key study and supporting study(ies) Different/ conflicting adequate information 3. RSS 3. RSS for key study 3. SS for supporting study(ies) WoE 3. RSS for all studies used as part of the Weight of Evidence (WoE) WoE Step 3: Draft

Step 2: Selection of key study

Step 2: Selection of key study Key study = study of greatest relevance the most suitable to describe an endpoint the basis for the risk assessment How to select key study(ies) Determine a key study for each endpoint based on the relevance, adequacy & reliability of the study(ies) usually the study which gives highest concern reliability indicator for a key study (Klimisch score) is 1-2

Step 2: Selection of key study

Evaluate the data 1.1 Relevance 1.2 Adequacy 1.3 Reliability Step 1: Evaluate Klimisch scoring 2. Adequate studies available? NO YES One adequate study YES More than one adequate study Less reliable studies Step 2: Select One key study One clear key study and supporting study(ies) Different/ conflicting adequate information 3. RSS 3. RSS for key study 3. SS for supporting study(ies) WoE 3. RSS for all studies used as part of the Weight of Evidence (WoE) WoE Step 3: Draft

Step 3: Drafting a Robust Study Summary WoE WoE 3. RSS 3. RSS for key study 3. SS for supporting study(ies) 3. RSS for all studies used as part of the Weight of Evidence (WoE)

Step 3: Drafting a Robust Study Summary (1) A detailed summary of the objectives, methods, results and conclusions of a full study report that provides sufficient information to make an independent assessment of the study, while minimising the need to consult the full study report [see: Article 3 (28)]. Level of detail needed?

Step 3: Drafting a Robust Study Summary (2) Robust Study Summary (RSS) contains as many details as necessary: To describe the test protocol and justify the validity of the result To assess the reliability and completeness of the study without having to go back to the full study report To assess whether the correct key study(ies) has/have been chosen for an endpoint IUCLID = Detail level 2 Basic fields + Additional information IUCLID display type = "all fields

Step 3: Drafting a Robust Study Summary (3) When is RSS required? if required under Annex I in the technical dossier (Article 10 (a)(vii)) This means: when CSR is required (substances at or above 10 tpa) for key studies

Step 3: Drafting a Robust Study Summary (4) RSS is recommended: for all key studies also for substances less than 10 tpa also for physico-chemistry end-points for all studies that are used as part of the Weight of Evidence (WoE) for non-key studies demonstrating a higher concern than a key study when the study gives ambiguous results when the study is performed according to non-standard protocols See: Guidance on registration, 8.2.2.6.2

Step 3: Drafting a Robust Study Summary (5) When using old studies: Physico-chemical, human health and environmental tests not performed according to test guideline and GLP Historical human data the information should be sufficient for Classification & Labelling and/or risk assessment the information should be scientifically valid adequate documentation must be provided

Step 3: Drafting a Robust Study Summary (6) What to provide for old studies: Robust Study Summary to enable ECHA to evaluate this non-standard data Need for justification when used as a key study justification ALWAYS needed Annex XI.1 No justification is needed if the study is submitted as a supportive study More deviations from the standard testing guideline more information needed to enable a good evaluation!!!

Step 3: Drafting a Robust Study Summary (7) Use of studies as supporting information: Valid study but reliability lower than that of key study Used in WoE and/or as supportive studies Registrant s specific tasks Report reasons why specific key study has been selected provide Study Summary for supportive studies BUT when supportive study indicates higher concern than the selected key study provide Robust Study Summary for supportive studies

Step 3: Drafting a Study Summary (1) A summary of the objectives, methods, results and conclusions of a full study report providing sufficient information to make an assessment of the relevance of the study [see: Article 3 (29)]. Level of detail needed?

Step 3: Drafting a Study Summary (2) Level of detail: Less detailed than RSS Information must be provided in sufficient detail to allow evaluation of the relevance of the study IUCLID = Detail level 1 Relevant for all study summaries IUCLID display type "basic fields as defined in the OECD harmonised templates. these fields should be completed for each study summary as far as possible.

Step 3: Drafting a Study Summary (3) When to provide: for key studies submitted for registration of substances manufactured/imported at 1-10 t/a (REACH Annex VI and VII) ECHA recommends to provide RSS for supportive studies Unless supportive study shows a higher concern than the key study

Experience so far Robust study summary quality show important differences in quality! Frequent errors: validity, reliability, repeatability criteria missing No independent evaluation possible poor reporting of test results Tabular or graphical form preferred unclear or insufficient level of detail on test material justifications for key study selection missing final conclusions at end of endpoint study record

Practical IUCLID tips How to fill in a robust study summary in IUCLID 5

Practical IUCLID tips When drafting RSS - Use the detail level 'all fields' in IUCLID technical dossier Guidance on registration, 8.2.2.6.1

Drafting RSS in IUCLID

Study Design Details on on inoculum Parameter followed for for biodegradation estimation estimation Details on on analytical methods Details on on study study design design

Practical IUCLID tips How to fill in the study summary in IUCLID 5

Practical IUCLID tips When drafting Study Summary - Use the detail level basic fields' in the IUCLID technical dossier Guidance on registration, 8.2.2.6.1

Drafting Study Summary in IUCLID

Study Design Any other information on on materials and and methods methods incl. incl. tables tables

Key messages and references GOOD DOCUMENTATION necessary for a reliable evaluation Key study Robust study summary References: Guidance on registration IUCLID 5 End User Manual Manual on robust study summaries